Canadian Agency for Drugs and Technologies in Health (CADTH)

Search within:  
Sort results by:      



1-6 of 6  
 
1.  
Guidance on 1.5 tesla magnetic resonance imaging scanners compared with 3.0 tesla magnetic resonance imaging scanners. 2011 May. NGC:008922
Canadian Agency for Drugs and Technologies in Health - Nonprofit Organization.
2.  
Optimal use recommendations for atypical antipsychotics: combination and high-dose treatment strategies in adolescents and adults with schizophrenia. 2011 Dec. NGC:009454
Canadian Agency for Drugs and Technologies in Health - Nonprofit Organization.
3.  
Optimal use recommendations for second- and third-line therapy for patients with type 2 diabetes. 2010 Aug (revised 2013 Jul). NGC:009997
Canadian Agency for Drugs and Technologies in Health - Nonprofit Organization.
4.  
Recommendations for antithrombotic agents for the prevention of stroke and systemic embolism in patients with atrial fibrillation. 2012 Jun (revised 2013 Mar). NGC:009802
Canadian Agency for Drugs and Technologies in Health - Nonprofit Organization.
5.  
Recommendations for drug therapies for relapsing-remitting multiple sclerosis. 2013 Oct. NGC:010418
Canadian Agency for Drugs and Technologies in Health - Nonprofit Organization.
6.  
Recommendations for optimal warfarin management for prevention of thromboembolic events in patients with atrial fibrillation. 2011 Nov. NGC:009453
Canadian Agency for Drugs and Technologies in Health - Nonprofit Organization.
1-6 of 6